ALUMIS INC (ALMS) Stock Price, Quote, News and Overview
NASDAQ:ALMS - Nasdaq - US0223071020 - Common Stock - Currency: USD
ALMS Quote, Performance and Key Statistics
ALUMIS INC
NASDAQ:ALMS (2/7/2025, 6:30:39 PM)
After market: 5.95 +0.28 (+4.94%)5.67
-0.92 (-13.96%)
The current stock price of ALMS is 5.67 USD. In the past month the price decreased by -26.27%.
ALMS Latest News and Analysis
What's going on in today's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
Alumis Strengthens Leadership Team with Key Appointments
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company....
ALMS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.56 | 833.80B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.18 | 383.72B | ||
| JNJ | JOHNSON & JOHNSON | 15.33 | 368.65B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.94 | 223.25B | ||
| MRK | MERCK & CO. INC. | 11.42 | 220.79B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.55 | 212.44B | ||
| PFE | PFIZER INC | 8.28 | 145.87B | ||
| SNY | SANOFI-ADR | 13.44 | 133.76B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 49.87 | 115.30B | ||
| ZTS | ZOETIS INC | 29.76 | 77.34B | ||
| GSK | GSK PLC-SPON ADR | 7.82 | 73.53B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.75 | 42.89B |
Related stock screener links
About ALMS
Company Profile
Alumis Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in South San Francisco, California and currently employs 145 full-time employees. The company went IPO on 2024-06-28. Alumis Inc. is a clinical-stage biopharmaceutical company. The company develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. The company builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. The company has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Company Info
ALUMIS INC
280 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 145
Company Website: https://www.alumis.com/
Phone: 16502316625
ALMS FAQ
What is the stock price of ALMS?
The current stock price of ALMS is 5.67 USD.
What is the symbol for ALUMIS INC stock?
The exchange symbol of ALUMIS INC is ALMS and it is listed on the Nasdaq exchange.
On which exchange is ALMS stock listed?
ALMS stock is listed on the Nasdaq exchange.
Is ALMS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ALMS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ALMS.
Does ALMS stock pay dividends?
ALMS does not pay a dividend.
What is the Price/Earnings (PE) ratio of ALMS?
ALMS does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.75).
What is the Short Interest ratio of ALMS stock?
The outstanding short interest for ALMS is 6.24% of its float.
ALMS Technical Analysis
ALMS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALMS. No worries on liquidiy or solvency for ALMS as it has an excellent financial health rating, but there are worries on the profitability.
ALMS Financial Highlights
Over the last trailing twelve months ALMS reported a non-GAAP Earnings per Share(EPS) of -6.75. The EPS decreased by -38.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.92% | ||
| ROE | -101.74% | ||
| Debt/Equity | 0 |
ALMS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to ALMS. The Buy consensus is the average rating of analysts ratings from 12 analysts.